Global Myotonic Dystrophy Drug Market Size, Share, Trends and Forecast 2022-2030

Description

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.

Industry Insights

Due to the COVID-19 pandemic, the global Myotonic Dystrophy Drug market size is estimated to be worth US$ 42 million in 2021 and is forecast to a readjusted size of US$ 67 million by 2028 with a CAGR of 6.8% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Myotonic Dystrophy Drug market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Myotonic Dystrophy Drug landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.

This report focuses on Myotonic Dystrophy Drug volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Myotonic Dystrophy Drug market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Myotonic Dystrophy Drug market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Sodium Channel Blocker

Tricyclic Antidepressant

Other

Segment by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Lupin

Teva

ANI Pharmaceuticals

Mylan

Novartis

Sun Pharma

Mallinckrodt

TABLE OF CONTENT

1 Myotonic Dystrophy Drug Market Overview
1.1 Product Overview and Scope of Myotonic Dystrophy Drug

1.2 Myotonic Dystrophy Drug Segment by Type

1.2.1 Global Myotonic Dystrophy Drug Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Sodium Channel Blocker

1.2.3 Tricyclic Antidepressant

1.2.4 Other

1.3 Myotonic Dystrophy Drug Segment by Distribution Channel

1.3.1 Global Myotonic Dystrophy Drug Sales Comparison by Distribution Channel: (2022-2028)

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Global Myotonic Dystrophy Drug Market Size Estimates and Forecasts

1.4.1 Global Myotonic Dystrophy Drug Revenue 2017-2028

1.4.2 Global Myotonic Dystrophy Drug Sales 2017-2028

1.4.3 Myotonic Dystrophy Drug Market Size by Region: 2017 Versus 2021 Versus 2028

2 Myotonic Dystrophy Drug Market Competition by Manufacturers

2.1 Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2017-2022)

2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Myotonic Dystrophy Drug Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Myotonic Dystrophy Drug Manufacturing Sites, Area Served, Product Type

2.5 Myotonic Dystrophy Drug Market Competitive Situation and Trends

2.5.1 Myotonic Dystrophy Drug Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Myotonic Dystrophy Drug Players Market Share by Revenue

2.5.3 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Myotonic Dystrophy Drug Retrospective Market Scenario by Region

3.1 Global Myotonic Dystrophy Drug Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Myotonic Dystrophy Drug Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Myotonic Dystrophy Drug Market Facts & Figures by Country

3.3.1 North America Myotonic Dystrophy Drug Sales by Country

3.3.2 North America Myotonic Dystrophy Drug Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe Myotonic Dystrophy Drug Market Facts & Figures by Country

3.4.1 Europe Myotonic Dystrophy Drug Sales by Country

3.4.2 Europe Myotonic Dystrophy Drug Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Myotonic Dystrophy Drug Market Facts & Figures by Region

3.5.1 Asia Pacific Myotonic Dystrophy Drug Sales by Region

3.5.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Myotonic Dystrophy Drug Market Facts & Figures by Country

3.6.1 Latin America Myotonic Dystrophy Drug Sales by Country

3.6.2 Latin America Myotonic Dystrophy Drug Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.6.6 Colombia

3.7 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Country

3.7.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Country

3.7.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Myotonic Dystrophy Drug Historic Market Analysis by Type

4.1 Global Myotonic Dystrophy Drug Sales Market Share by Type (2017-2022)

4.2 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2017-2022)

4.3 Global Myotonic Dystrophy Drug Price by Type (2017-2022)

5 Global Myotonic Dystrophy Drug Historic Market Analysis by Distribution Channel

5.1 Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2017-2022)

5.2 Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2017-2022)

5.3 Global Myotonic Dystrophy Drug Price by Distribution Channel (2017-2022)

6 Key Companies Profiled

6.1 Lupin

6.1.1 Lupin Corporation Information

6.1.2 Lupin Description and Business Overview

6.1.3 Lupin Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Lupin Myotonic Dystrophy Drug Product Portfolio

6.1.5 Lupin Recent Developments/Updates

6.2 Teva

6.2.1 Teva Corporation Information

6.2.2 Teva Description and Business Overview

6.2.3 Teva Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Teva Myotonic Dystrophy Drug Product Portfolio

6.2.5 Teva Recent Developments/Updates

6.3 ANI Pharmaceuticals

6.3.1 ANI Pharmaceuticals Corporation Information

6.3.2 ANI Pharmaceuticals Description and Business Overview

6.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio

6.3.5 ANI Pharmaceuticals Recent Developments/Updates

6.4 Mylan

6.4.1 Mylan Corporation Information

6.4.2 Mylan Description and Business Overview

6.4.3 Mylan Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Mylan Myotonic Dystrophy Drug Product Portfolio

6.4.5 Mylan Recent Developments/Updates

6.5 Novartis

6.5.1 Novartis Corporation Information

6.5.2 Novartis Description and Business Overview

6.5.3 Novartis Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Novartis Myotonic Dystrophy Drug Product Portfolio

6.5.5 Novartis Recent Developments/Updates

6.6 Sun Pharma

6.6.1 Sun Pharma Corporation Information

6.6.2 Sun Pharma Description and Business Overview

6.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Sun Pharma Myotonic Dystrophy Drug Product Portfolio

6.6.5 Sun Pharma Recent Developments/Updates

6.7 Mallinckrodt

6.6.1 Mallinckrodt Corporation Information

6.6.2 Mallinckrodt Description and Business Overview

6.6.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Mallinckrodt Myotonic Dystrophy Drug Product Portfolio

6.7.5 Mallinckrodt Recent Developments/Updates

7 Myotonic Dystrophy Drug Manufacturing Cost Analysis

7.1 Myotonic Dystrophy Drug Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Myotonic Dystrophy Drug

7.4 Myotonic Dystrophy Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Myotonic Dystrophy Drug Distributors List

8.3 Myotonic Dystrophy Drug Customers

9 Myotonic Dystrophy Drug Market Dynamics

9.1 Myotonic Dystrophy Drug Industry Trends

9.2 Myotonic Dystrophy Drug Market Drivers

9.3 Myotonic Dystrophy Drug Market Challenges

9.4 Myotonic Dystrophy Drug Market Restraints

10 Global Market Forecast

10.1 Myotonic Dystrophy Drug Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Myotonic Dystrophy Drug by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Myotonic Dystrophy Drug by Type (2023-2028)

10.2 Myotonic Dystrophy Drug Market Estimates and Projections by Distribution Channel

10.2.1 Global Forecasted Sales of Myotonic Dystrophy Drug by Distribution Channel (2023-2028)

10.2.2 Global Forecasted Revenue of Myotonic Dystrophy Drug by Distribution Channel (2023-2028)

10.3 Myotonic Dystrophy Drug Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Myotonic Dystrophy Drug by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Myotonic Dystrophy Drug by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample